{"id":"W4387811438","doi":"10.1016/j.annonc.2023.09.1878","title":"692P First-in-human study of ELU001, a targeted nanoparticle drug conjugate, in subjects with folate receptor α (FRα) overexpressing solid tumors","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Cilag; Chugai Pharmaceutical; Aptitude Health; Centre Léon Bérard; PharmaMar; Basilea Pharmaceutica; Eisai; Eisai Canada; BeiGene; Clovis Oncology; Loxo Oncology; Astex Pharmaceuticals; Les Laboratories Pierre Fabre; Memorial Sloan-Kettering Cancer Center; Genentech; Institut Gustave-Roussy; Daiichi Sankyo Europe; Servier; Gilead Sciences; Bayer HealthCare; Exelixis; Sanofi; Pfizer; Incyte; Boston Pharmaceuticals; F. Hoffmann-La Roche; Seagen; Agios Pharmaceuticals; Roche; Amgen; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Neutropenia; Folate receptor; Anemia; Internal medicine; Regimen; Adverse effect; Toxicity; Gastroenterology; Conjugate; Pharmacology; Cancer; Cancer cell","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000732689,0.001107452,0.001553946,0.0003436779,0.0007061192,0.0007931103,0.0003830408,0.001141974,0.002816722],"category_scores_gemma":[0.0004660531,0.0004647237,0.0007790427,0.0002707206,0.001087302,0.0007616048,0.0002460618,0.002331501,0.0008898205],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007580275,"about_ca_system_score_gemma":0.001016221,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004882319,"about_ca_topic_score_gemma":0.003380006,"domain_scores_codex":[0.9997509,0.00006716356,0.000005765883,0.00006300948,0.00002119297,0.00009192462],"domain_scores_gemma":[0.9996765,0.00006556575,0.00003280278,0.00004213623,0.00003628358,0.0001468506],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6603631,0.1464539,0.01449334,0.0003080813,0.0007220697,0.001554396,0.0006482225,0.001531584,0.1211325,0.0002536031,0.002279582,0.05025976],"study_design_scores_gemma":[0.01691278,0.921234,0.02340022,0.00001331938,0.000659278,0.0005048577,0.0003215012,0.001387188,0.03155986,0.0001431354,0.003810369,0.00005366605],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9969155,0.0003973678,0.0004652991,0.00007281578,0.00004773404,0.0003767381,0.0004517386,0.00003889532,0.001233988],"genre_scores_gemma":[0.9937103,0.0004096922,0.0003015723,0.0001851523,0.00005637807,0.0002756815,0.0007057079,0.00002735516,0.004328151],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004882319,"threshold_uncertainty_score":0.009707749,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09242421790982693,"score_gpt":0.432836990109584,"score_spread":0.3404127721997571,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}